Terms & Conditions

The information on Oculaudio web site that requires log in access is confidential and will be regulated by this agreement. All copying, screenshots or other methods to distribute the content will be followed up by legal acts.

The Recipient who has ticked off the box TERMS AND CONDITIONS understand and agree that the Oculaudio web page (www.oculaudio.com) will disclose confidential information. The Recipient also confirm that all information in this Terms and conditions has been read and understood.To ensure the protection of such information the Recipient agrees as follows:

“Confidential Information” means all information disclosed by the Discloser or any of the Discloser’s representatives to the Recipient or any of the Recipient’s representatives in connection with the Purpose, whether in oral, written, graphic, or electronic form, including, but not limited to, trade secrets, know-how, ideas, inventions, techniques, technology, contracts, customer lists, financial information, sales and marketing plans and business plans. Furthermore, the discussions between the Discloser and the Recipient regarding the Purpose constitutes Confidential Information.
The Recipient shall treat all Confidential Information strictly confidential, and shall not in any manner or form disclose, provide or otherwise make available, in whole or in part, the Confidential Information or any related material.
The Recipient shall examine and use the Confidential Information solely for the purpose of considering possible future co-operation, and for no other purpose whatsoever.
The Recipient has no right to copy or reproduce in any form the Confidential Information, in whole or in part, except if authorized in written by the Discloser.
All materials in any form containing Confidential Information, or any copies of such, shall be returned to the Discloser at any time upon the request of the Discloser.
The Recipient may only provide Confidential Information to its employees if authorized in written by the Discloser. The Recipient shall ensure that all employees receiving Confidential Informationshall have executed this or a similar non-disclosure agreement with terms at least as restrictive as those specified in this NDA. Such disclosure shall be in confidence for purposes specially related to Recipient’s work with the Confidential Information.
This NDA and the Recipient’s obligations hereunder shall be binding on all of the Recipient’s representatives, including employees, agents and others assisting the Recipient, and all assigns and successors of the Recipient, and shall inure to the benefit of the assigns and successors of the Discloser.
The Recipient shall take all steps necessary to ensure the protection, confidentiality and security of the Confidential Information or any related materials and to satisfy its obligations under this NDA.
The Recipient will immediately give notice to the Discloser of any unauthorized use or disclosure of the Confidential Information. The Recipient shall take all steps necessary to remedy any unauthorized use or disclosure of the Confidential Information.
The Recipient shall fully compensate the Discloser for any loss or costs related to any disclosure or misappropriation of any of the Confidential Information in violation of this NDA, or any other breach of this NDA.
The Recipient understands and acknowledges that any disclosure or misappropriation of any of the Confidential Information in violation of this NDA may cause Discloser irreparable harm, the amount of which may be difficult to ascertain and, therefore, agrees that Discloser shall have the right to apply to a court of competent jurisdiction for an order restraining any such further disclosure or misappropriation and for such other equitable relief as Discloser shall deem appropriate.
All Confidential Information (including all copies, extracts and portions thereof) shall be and remain the sole property of the Discloser. The Recipient does not acquire (by license or otherwise, whether expressly or impliedly) any intellectual property rights or any other rights under this NDA or any disclosure hereunder, except the limited right to use such Confidential Information in accordance with this NDA. No warranties of any kind, whether express or implied, are given with respect to any Confidential Information or any use thereof, except as may be otherwise agreed to in writing.
This NDA shall continue in full force and effect for a period of five (5) years from the Effective Date. The termination of this NDA shall not release the Recipient from the obligations hereunder with respect to Confidential Information disclosed prior to termination.
The NDA shall be governed by and construed in accordance with the laws of Norway. Any dispute arising out of or in connection with this NDA, which cannot be amicably solved by mutual agreement, shall be referred to arbitration in Oslo in accordance with the Norwegian Arbitration Act. The arbitration shall be confidential.

This Confidential Presentation, also for potentially Investors (the “Investor Presentation”) of OculAudio AS (“OculAudio” or “the Company”) has been prepared solely for information purposes and for the sole use of the person and/or to whom it is delivered. This Investor Presentation may not be distributed, reproduced, or used without the consent of the Company or for any purpose other than the evaluation of the Company and it Business Plan (the “Business Pan”) by the person to whom this Investor or interesting party Presentation is delivered.
This Investor Presentation is provided subject to the terms and the prior execution of a confidentiality and non-solicitation undertaking (the “Confidentiality Undertaking”). In receiving this Investor Presentation, potential investors confirm that the Investor Presentation and related material received will be used for the stated purpose only and in accordance with the terms and the conditions of the Confidentiality Undertaking.
The information contained herein has been prepared to assist outside parties in making their own evaluation of the Company, its Business Plan, and investment in shares in the Company, and does not purport to contain all information that such interested parties may desire or require in order to make a decision to proceed with an investment in the Company. Interested parties should conduct their own investigations and analyses of the Company, the relevant market, and the data set forth in this Investor Presentation, including the projections and assumptions reflected herein.

The product that will be manufactured may be different from the presentation.
No party has made any kind of independent verification of any of the information set out herein, including any statements with respect to projections or prospects of the Company or the assumptions on which such statements are based, and does not undertake any obligation to do so. The Company, its employees, directors, shareholders, or advisors make no representations or warranty, express or implied, as to the accuracy or completeness of this Investor Presentation or of the information contained herein and shall have no liability for the information contained in, or any omissions from, this Investor Presentation, nor for any of the written, electronic or oral communications transmitted to the recipient in the course of the recipient’s own investigation and evaluation of the Company.
Included in this Investor Presentation are various “forward-looking statements”, including statements regarding the intent, opinion, belief or current expectations of the Company or its management with respect to, among other things, (i) goals and strategies, (ii) plans for new product development, (iii) marketing plans, the Company’s target market, (iv) evaluation of the Company’s markets, competition and competitive position, and (v) trends which may be expressed or implied by financial or other information or statements contained herein. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance and outcomes to be materially different from any future results, performance or outcomes expressed or implied by such forward-looking statements.
Neither the receipt of this Investor Presentation by any person, nor any information contained herein constitutes, or shall be relied upon as constituting, any advice relating to the future performance of the Company. Each person should make their own independent assessment and should consult their own professional advisors.
This document is being circulated on a restricted and confidential basis. Applications for shares (if any) will only be considered on the terms of the final subscription documents if and when issued. This document has not been approved by any competent authority. Statements herein include statements of circumstances which may exist at the dates upon which the final subscription is completed, but which may not exist at the present time.
The Investor Presentation and this disclaimer shall be governed and construed in accordance with the laws of Norway and Norwegian courts as exclusive legal venue. By retaining this Investor Presentation, recipients confirm that they have read, understood and accepted the terms of this disclaimer.

International Business to Business AS is the owner of Oculaudio AS and SMTM AS and is holding all the Pattens and IP-rights of Oculaudio AS and SMTM AS. Oculaudio AS is developing the Hearing aid glasses and ear buds, SMTM AS is developing the inteligent expanding/actuator Polymer part of the Ear Buds .
Communication or inquiries relating to the Company and/or this Investor Presentation should only be directed to the following representatives of the Company:

Tom Austad
tom@oculaudio.com